home / stock / bgne / bgne quote
Last: | $147.87 |
---|---|
Change Percent: | 2.6% |
Open: | $148.4 |
Close: | $144.12 |
High: | $149 |
Low: | $146.16 |
Volume: | 56,712 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$147.87 | $148.4 | $144.12 | $149 | $146.16 | 56,712 | 04-25-2024 |
$144.12 | $143.45 | $144.12 | $146.22 | $141.78 | 215,587 | 04-24-2024 |
$138.99 | $135.75 | $138.99 | $142.22 | $134.68 | 203,615 | 04-23-2024 |
$130.94 | $130.55 | $130.94 | $133.09 | $129.96 | 152,563 | 04-22-2024 |
$129.52 | $130 | $129.52 | $130.85 | $126.9681 | 296,412 | 04-19-2024 |
$131.96 | $131.4 | $131.96 | $136 | $131.4 | 125,955 | 04-18-2024 |
$131.86 | $134.4 | $131.86 | $134.4 | $131.2794 | 200,058 | 04-17-2024 |
$134.05 | $137.28 | $134.05 | $137.705 | $133.71 | 308,982 | 04-16-2024 |
$138.4 | $140.68 | $138.4 | $142.63 | $137.375 | 228,159 | 04-15-2024 |
$141.3 | $145 | $141.3 | $146.805 | $140.08 | 139,454 | 04-12-2024 |
$146.13 | $147.62 | $146.13 | $148.93 | $145.34 | 243,171 | 04-11-2024 |
$149.76 | $150.34 | $149.76 | $150.975 | $147.975 | 272,924 | 04-10-2024 |
$154.02 | $153.7 | $154.02 | $155.37 | $150.84 | 115,201 | 04-09-2024 |
$149.75 | $148.84 | $149.75 | $151.52 | $148.5 | 109,180 | 04-08-2024 |
$150.03 | $149.57 | $150.03 | $151.445 | $148 | 90,661 | 04-05-2024 |
$149.57 | $153.26 | $149.57 | $153.28 | $149.3 | 81,654 | 04-04-2024 |
$151.95 | $153.53 | $151.95 | $154.1224 | $150.79 | 56,991 | 04-03-2024 |
$153.25 | $155.51 | $153.25 | $157.32 | $152.695 | 84,095 | 04-02-2024 |
$159.23 | $156.87 | $159.23 | $159.34 | $152.77 | 126,964 | 04-01-2024 |
$156.39 | $157 | $156.39 | $157.38 | $155.09 | 104,129 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Multiple presentations to showcase the efficacy and safety of BRUKINSA ® across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA ® in advanced or metastatic esophageal squamous cell carcinoma (ESCC) Be...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s second approval in the region BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0...